Costa L - Search Results

1

Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer.

Willumsen N, Ali SM, Leitzel K, Drabick JJ, Yee N, Polimera HV, Nagabhairu V, Krecko L, Ali A, Maddukuri A, Moku P, Ali A, Poulose J, Menon H, Pancholy N, Costa L, Karsdal MA, Lipton A. Willumsen N, et al. Among authors: costa l. Sci Rep. 2019 Dec 24;9(1):19761. doi: 10.1038/s41598-019-56268-3. Sci Rep. 2019. PMID: 31875000 Free PMC article. Clinical Trial.

2

Biochemical markers of bone turnover in patients with metastatic bone disease.

Demers LM, Costa L, Chinchilli VM, Gaydos L, Curley E, Lipton A. Demers LM, et al. Among authors: costa l. Clin Chem. 1995 Oct;41(10):1489-94. Clin Chem. 1995. PMID: 7586522

3

Bone markers in osteoporosis and malignancy.

Lipton A, Costa L, Demers LM. Lipton A, et al. Among authors: costa l. Can J Oncol. 1995 Dec;5 Suppl 1:11-5. Can J Oncol. 1995. PMID: 8853519

4

Biochemical markers and skeletal metastases.

Demers LM, Costa L, Lipton A. Demers LM, et al. Among authors: costa l. Cancer. 2000 Jun 15;88(12 Suppl):2919-26. doi: 10.1002/1097-0142(20000615)88:12+<2919::aid-cncr7>3.0.co;2-z. Cancer. 2000. PMID: 10898335 Review.

5

Bone markers in the management of metastatic bone disease.

Lipton A, Costa L, Ali SM, Demers LM. Lipton A, et al. Among authors: costa l. Cancer Treat Rev. 2001 Jun;27(3):181-5. doi: 10.1053/ctrv.2000.0212. Cancer Treat Rev. 2001. PMID: 11417969 Review.

6

Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.

Ali SM, Esteva FJ, Hortobagyi G, Harvey H, Seaman J, Knight R, Costa L, Lipton A. Ali SM, et al. Among authors: costa l. J Clin Oncol. 2001 Jul 15;19(14):3434-7. doi: 10.1200/JCO.2001.19.14.3434. J Clin Oncol. 2001. PMID: 11454892 Clinical Trial.

7

Use of markers of bone turnover for monitoring bone metastases and the response to therapy.

Lipton A, Costa L, Ali S, Demers L. Lipton A, et al. Among authors: costa l. Semin Oncol. 2001 Aug;28(4 Suppl 11):54-9. doi: 10.1016/s0093-7754(01)90233-7. Semin Oncol. 2001. PMID: 11544577 Review.

8

Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.

Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC, Lipton A. Costa L, et al. Among authors: costa eb. J Clin Oncol. 2002 Feb 1;20(3):850-6. doi: 10.1200/JCO.2002.20.3.850. J Clin Oncol. 2002. PMID: 11821470

9

Biochemical markers and skeletal metastases.

Demers LM, Costa L, Lipton A. Demers LM, et al. Among authors: costa l. Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S138-47. doi: 10.1097/01.blo.0000092979.12414.54. Clin Orthop Relat Res. 2003. PMID: 14600604 Review.

10

Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis.

Ali SM, Demers LM, Leitzel K, Harvey HA, Clemens D, Mallinak N, Engle L, Chinchilli V, Costa L, Brady C, Seaman J, Lipton A. Ali SM, et al. Among authors: costa l. Ann Oncol. 2004 Mar;15(3):455-9. doi: 10.1093/annonc/mdh089. Ann Oncol. 2004. PMID: 14998848 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,435 results

Search Page

Filters